Inflammation of the heart muscle is called myocarditis, whereas inflammation of the membrane around the heart is called pericarditis. In both circumstances, the body’s immunological reaction to an infection or other trigger results in inflammation. The Centers for Disease Control and Prevention released definitions of myocarditis and pericarditis.
Pericarditis and myocarditis can range in severity. Most individuals who sought medical attention after developing symptoms of myocarditis or pericarditis after receiving an mRNA COVID-19 vaccine reacted well to treatment, and their conditions improved rapidly. The CDC is studying myocarditis outcomes following mRNA COVID-19 immunization. Surveys done at least 90 days following a diagnosis of myocarditis indicated that most patients had fully recovered.
Inflammation of the heart (myocarditis): a side effect of the COVID-19 vaccine?
Myocarditis, or heart muscle inflammation, has been reported after some people in the UK received the Moderna vaccination or, even less often, the Pfizer vaccine.
Due to the extremely low number of reported occurrences of myocarditis during Novavax clinical trials, this condition is now officially recognized as a potential adverse effect of the vaccine.
Myocarditis reports after receiving any COVID-19 vaccination remain uncommon, and when they do occur, they tend to be minor. Those afflicted typically feel better after rest and trying home remedies. The majority of people with myocarditis recover to normal cardiac function.
According to the available data, the COVIDvaccination is no more likely than any other vaccine to cause myocarditis.
Myocarditis is a rare side effect of the COVID-19 vaccination, and those who have it are far less likely to get other major consequences due to the virus.
What is the risk of getting myocarditis or pericarditis after the vaccine?
After receiving the vaccination, your chance of developing myocarditis or pericarditis is extremely low.
Only 29 occurrences of suspected myocarditis or pericarditis were reported for every million-second dose of the Pfizer vaccine administered in the UK, and this was in the highest-risk age range (18-29). (up until 24 August 2022). With only 17 new instances per million persons in this age range, the danger is significantly lower after receiving a Pfizer booster. The danger is significantly smaller in other age groups.
In the United Kingdom, for every million-second dose of Moderna administered, there were 68 occurrences of probable myocarditis or pericarditis in this age range. Similarly, after receiving a booster dose of the Pfizer vaccine, the risk is significantly reduced, with just 23 reports per million boosters administered (up until 24 August 2022). However, the danger is significantly smaller for those of different ages.
According to the WHO’s analysis, as of 30 April 2022, a total of 744,235 doses of the Novavax vaccine have been administered in Australia, New Zealand, Canada, the European Union, and South Korea. There were reports of myocarditis in 4, pericarditis in 29, and myopericarditis in 2 of these individuals. Seven incidences of myocarditis and 26 cases of suspected pericarditis were reported after 209,000 doses of the Novavax COVID vaccination in Australia as of 21 August 2022.
Incredibly, serious occurrences of myocarditis following vaccination have been extremely uncommon; nevertheless, additional study into the long-term implications is currently underway.
Prevent infection and transmission
People who have ever had a serious adverse response to any part of the vaccination should avoid this one and any others that use mRNA.
If a person has myocarditis or pericarditis after receiving their first dose of the mRNA-1273 vaccination, they should not get any future doses of any COVID vaccine without consulting their doctor.
